Randomized double blind placebo-controlled study of a new formulation in combination with 5% benzoyl peroxide in the treatment of facial acne vulgaris

B. DRENO¹, A. KHAMMARI¹, A. ROUGIER², S. SEITE²

  • Mai. 2024
  • Desenvolvido por:
  • La Roche-Posay

INTRODUCTION

Benzoyl peroxide (BPO) is a highly lipophilic oxidizing agent with bactericidal and keratolytic effects. It is a gold standard for papular-pustular acne. However, its use can cause mild skin irritation and dryness. It would be interesting to combine BPO with other treatments in order to obtain the same clinical efficacy on inflammatory and non-inflammatory acne lesions and a better tolerability and, therefore, compliance. The aim of this randomized double-blind placebo-controlled study was to evaluate a new formulation containing: Lipohydroxy acid (LHA), Salicylic acid (SA), Linoleic acid, Niacinamide and Piroctone Olamine in combination with 5% benzoyl peroxide (BPO) in subjects with acne vulgaris.


Content

¹Department of Dermato Oncology, Hôtel Dieu, CHU Nantes, France, ²La Roche-Posay Dermatological Laboratories, Asnières, France